with Dr. Sanjit S. Jolly
Patients experiencing myocardial infarction (MI) remain at high risk of future major adverse cardiovascular events (MACE). While low-dose colchicine and spironolactone have been shown to decrease post-MI MACE, more data are required to confirm their safety and efficacy in an unselected post-MI population. Therefore, study authors initiated the CLEAR SYNERGY (OASIS 9) trial to address these uncertainties.
Read more about the study here.
Panelists
Presenter
